The Group possesses clinical need-oriented product identification and project initiation capabilities, validated clinical development and commercialization expertise, as well as abundant cash flow. Leveraging our core advantages, we fuel innovation through the dual engines of collaborative R&D and in-house R&D, continuously enrich our innovation pipeline centered on first-in-class (FIC) and best-in-class* (BIC) products, and efficiently advance the clinical development and commercialization, so as to deliver more quality pharmaceutical solutions for patients.
*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems
Innovative Pipeline Products
projects have been prepared for/are processing their registrational clinical trials, mainly randomized controlled trials (RCT).
Approved for Marketing in China
*Unless otherwise stated, the above data are as at December 31, 2024
We expand our differentiated innovation pipeline in mid-to-late clinical stages through industrial investments or strategic collaborations. Leveraging our capabilities and resources, we efficiently advance the clinical development, registration, and commercialization of products in China and other licensed countries/regions, accelerating the implementation of pharmaceutical innovation.
Starting from forward-looking scientific insights and unmet clinical needs, we focus on our advantageous specialty fields, concentrate on novel targets and cutting-edge biotechnologies, and independently advance the entire lifecycle management of innovative drugs to build a proprietary intellectual property pipeline with global influence.
We have established an in-house clinical development system focused on the four key components: medical, clinical, pharmacovigilance and quality assurance. The process is overseen to provide high-level confidence that the medical strategy is rational, clinical operations are effective and compliant, and product safety risks are controllable.
Proven clinical enrollment capability:
*Tildrakizumab Solution for Injection- Completed
enrollment of all the 220 subjects within 2.5 months (including the Chinese Spring Festival
holidays)
*Methylthioninium Chloride Enteric-coated
Sustained-release Tablets- Completed enrollment of all the 1,800 subjects within 6 months (including the
Chinese Spring Festival holidays)
